[Repeated yearly BCG treatment in superficial bladder cancer].
The authors report on experiences of treatment for superficial bladder cancer with BCG have achieved during three years. To achieve a permanent recidive prophylaxis the 6 weeks long course was repeated yearly. During the 37-12 months follow up a tumor recurrence have been observed in 10 of 49 patients (20.4%). There have not been seen any serious side-effects requering the interruption of the course or requering any antituberculotica. On the basis of their results and the torelable side-effects they recommend the local BCG treatment as a favourable possibility in prevention of bladder tumor recurrence.
Somogyi
L
L
Török
A
A
Bors
G
G
Drinóczy
M
M
Horváth
R
R
D001500:BCG Vaccine / Q000627:therapeutic use*; D002277:Carcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D005260:Female; D007167:Immunotherapy; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D009367:Neoplasm Staging; D010212:Papilloma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D014374:Tuberculin Test; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D001500:BCG Vaccine
Felületes hólyagdaganatok évenként ismételt BCG kezelése.